anorexia-cachexia

anorexia-cachexia

 
a systemic response to cancer occurring as a result of metabolites which may be produced by the tumor cells and released into the blood stream, stimulating the satiety center in the hypothalamus and producing appetite loss, gross alterations of metabolic patterns, and a profound systemic confusion which may result in further anorexia. This leads to malnutrition, weight loss, muscular weakness, and a negative nitrogen balance that contributes to the development of cachectic wasting.
References in periodicals archive ?
Anamorelin is a new first-in-class, oral, once daily drug, currently in phase III for the treatment of anorexia-cachexia in NSCLC, a detrimental multifactorial disorder that affects over 50% of people with cancer and in which systemic inflammation, reduced food intake and altered metabolism contribute to loss of muscle mass and reduction of body weight leading to reduced quality of life, functional impairment and decreased survival.
UOMO, G; GALLUCCI, F & RABITTI, PG 2006: Anorexia-cachexia syndrome in pancreatic cancer: Recent development in research and management.
This approval will allow the company to commence clinical trials in patients with histologically confirmed malignancies who present with clinically demonstrable anorexia or anorexia-cachexia syndrome.
Anamorelin is a novel ghrelin receptor agonist in development for the treatment of cancer anorexia-cachexia syndrome
By mimicking ghrelin, the so-called "hunger hormone" secreted by the gastrointestinal tract, anamorelin was shown to increase lean body mass and improve appetite in patients with non-small cell lung cancer who are suffering from Cancer Anorexia-Cachexia in two pivotal large-scale 12-week Phase III studies, ROMANA 1 and ROMANA 2.
At present, in Anamorelin is a new first-in-class, oralc, in phase III for the treatment of anorexia-cachexia in NSCLC, a detrimental multifactorial disarray that affects over 50% of people with cancer and in which systemic inflammation, reduced food intake and altered metabolism contribute to loss of muscle mass and reduction of body weight leading to reduced quality of life.
In addition to this symposium, Helsinn submitted 10 abstracts to the MASCC Annual Meeting on a range of topics relating to supportive care in cancer treatment, including management of CINV, cancer anorexia-cachexia and mucositis.
Anamorelin is a novel, once-daily, orally active ghrelin receptor agonist under investigation for the treatment of Cancer Anorexia-Cachexia in patients suffering from non-small cell lung cancer (NSCLC), an area of significant unmet medical need.
Cancer Anorexia-Cachexia Syndrome is a multifactorial syndrome that negatively impacts the functional performance, quality of life and prognosis of cancer patients.
Helsinn Group, the Company focused on building quality cancer care, announces that anamorelin, its investigational novel once-daily ghrelin receptor agonist for the treatment of cancer anorexia-cachexia syndrome (CACS), delivered significant improvements in lean body mass[LBM; one of two primary endpoints] in ROMANA 1, a pivotal 12-week Phase III study in non-small cell lung cancer (NSCLC) patients.